A new three-year initiative from the American Heart Association (AHA) is seeking to improve how clinicians identify and manage cardiac amyloidosis. It was once considered a rare disease, but experts now recognize it is a more common cause of heart failure.
The ATTR-CM Discovery Initiative brings together multidisciplinary teams to strengthen the awareness, diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The goal is to catch patients early before they progress and develop advanced heart failure. Cardiovascular Business discussed the initiative with Mathew S. Maurer, MD, a volunteer member of the AHA ATTR Amyloidosis Strategic Advisory Group guiding the initiative. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center and director of the cardiac amyloidosis program at NewYork-Presbyterian/Columbia University Irving Medical Center.